Novartis sells off blood diagnostics division


Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion (£1 billion). The sale will allow the company to ‘focus more sharply on [its] strategic businesses’, according to chief executive Joseph Jimenez.

Novartis acquired the blood diagnostics unit when it bought Chiron in 2006. The main point of that acquisition was to kick start their vaccine development programme. Novartis has since developed new influenza vaccines that can be produced faster than methods based on chicken eggs, for example.


Related Content

Novartis in the spotlight in mis-selling investigations

9 January 2014 Business

news image

Crackdown on pharma marketing continues with US and Japanese cases

$25bn-plus trade sharpens pharma giants’ focus

25 April 2014 Business

news image

Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint